LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

Inicio・Lista de Acciones・Incyte Corp

Incyte Corp

Abierto

SectorSanidad

96.62 -0.86

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

96.18

Máximo

97.81

Métricas clave
By Trading Economics
Ingresos	4.1M 303M
Ventas	-234M 1.3B
P/B Media del Sector	13.723 50.102
BPA	1.81
Margen de beneficios	23.834
Empleados	2,844
EBITDA	-47M 368M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+11.25% upside

Dividendos
By Dow Jones
Próximas Ganancias	28 jul 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	362M 19B
Apertura anterior	97.48
Cierre anterior	96.62

Noticias sobre sentimiento de mercado

By Acuity

58%

42%

277 / 344 Clasificación en Healthcare

Incyte Corp Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

28 may 2026, 22:47 UTC

Ganancias

Costco 3Q Sales Rise as Value Offerings Draw Pressured Consumers -- Update

28 may 2026, 20:45 UTC

Ganancias

Costco 3Q Profit Rises as Value Offerings Draw Pressured Consumers

28 may 2026, 23:43 UTC

Charlas de Mercado

Nikkei May Rise on Hopes for U.S.-Iran Peace Deal -- Market Talk

28 may 2026, 23:39 UTC

Charlas de Mercado

Gold Edges Lower as Traders Assess Potential U.S.-Iran Deal -- Market Talk

28 may 2026, 23:31 UTC

Charlas de Mercado

KMD Could Realize Value From Selling Either Oboz or Rip Curl -- Market Talk

28 may 2026, 23:17 UTC

Charlas de Mercado

Mainfreight Steering Its Way Out of Tough Period -- Market Talk

28 may 2026, 23:02 UTC

Charlas de Mercado

Costco Has Started Submitting Tariff Refund Claims -- Market Talk

28 may 2026, 22:41 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

28 may 2026, 22:41 UTC

Charlas de Mercado

MongoDB Still Getting More Growth From Established Customers Than AI -- Market Talk

28 may 2026, 22:37 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

M&A-Related Insurance Payments In North America Rise -- Market Talk

28 may 2026, 22:04 UTC

Adquisiciones, fusiones, absorciones

CN: Surface Transportation Board Was Right to Freeze the UP-NS Merger and Demand More Info

28 may 2026, 22:04 UTC

Adquisiciones, fusiones, absorciones

CN: This Confirms What CN and Many Stakeholders Have Said All Along, UP and NS Still Have Not Submitted a Credible Case to Support Their Proposed Merger >CNI

28 may 2026, 21:12 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Synopsys Was the Worst S&P 500 Stock Thursday Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

28 may 2026, 21:00 UTC

Ganancias

Dell Stock Soars on Blowout Earnings. The Outlook Bests Analysts by $20 Billion. -- Barrons.com

28 may 2026, 20:57 UTC

Ganancias

Dell Stock Soars on Blowout Earnings -- Barrons.com

28 may 2026, 20:55 UTC

Ganancias

Costco Wholesale Sees a Mixed Quarter, Misses Earnings Estimates -- Barrons.com

28 may 2026, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

28 may 2026, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

28 may 2026, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

28 may 2026, 20:48 UTC

Acciones populares

Stocks to Watch Recap: Snowflake, Union Pacific, Hormel Foods -- WSJ

28 may 2026, 20:34 UTC

Ganancias

One of the S&P 500's Highest Dividends Looks Even Better Now -- Barrons.com

28 may 2026, 20:31 UTC

Ganancias

Li and XPeng Both Miss Earnings Estimates. One Chinese EV Maker's Stock Is Rising. -- Barrons.com

28 may 2026, 20:28 UTC

Ganancias

Best Buy's 5% Dividend Yield Looks Even Better After Earnings -- Barrons.com

28 may 2026, 20:26 UTC

Ganancias

Dell Stock Soars on Blowout Earnings -- Barrons.com

28 may 2026, 20:20 UTC

Ganancias

Costco 3Q Membership Fees $1.37B

28 may 2026, 20:20 UTC

Ganancias

Costco 3Q Net Sales $69.15B

28 may 2026, 20:19 UTC

Ganancias

Costco 3Q Adj Same-Store Sales, Which Excludes Impacts From Gas Prices and Foreign Exchange, Rose 6.6% >COST

28 may 2026, 20:19 UTC

Ganancias

Costco 3Q Adjusted Digitally-Enabled Sales Rose 20.8% >COST

28 may 2026, 20:17 UTC

Ganancias

Costco 3Q Digitally-Enabled Sales Rose 21.5% >COST

28 may 2026, 20:17 UTC

Ganancias

Costco 3Q Same-Store Sales Up 9.8% >COST

Comparación entre iguales

Cambio de precio

Incyte Corp previsión

Precio Objetivo

By TipRanks

11.25% repunte

Estimación a 12 Meses

Media 108.29 USD 11.25%

Máximo 135 USD

Mínimo 75 USD

De acuerdo con 19 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Incyte Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

19 ratings

Comprar

Mantener

Vender

De acuerdo con 19 analistas que ofrecen calificaciones bursátiles a para Incyte Corp Dist en los últimos 3 meses.

Sentimiento

By Acuity

277 / 344 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation